Welgene Biotech Co.,Ltd. (TPEX:6661)
Taiwan · Delayed Price · Currency is TWD 17.20
0.00 (0.00%)
Oct 7, 2026, 9:00 AM CST
Welgene Biotech Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 6, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 401 | 433 | 555 | 521 | 517 | 570 | |
Market Cap Growth | -26.18% | -21.85% | 6.49% | 0.68% | -9.20% | -23.98% |
Enterprise Value | 485 | 350 | 499 | 500 | 317 | 410 |
Last Close Price | 17.20 | 18.60 | 23.80 | 22.35 | 22.02 | 23.69 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 6, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | 325.91 | 501.03 | - | 54.16 | 41.58 |
Forward PE | - | 18.50 | 18.50 | 18.50 | 18.50 | 18.50 |
PS Ratio | 1.00 | 1.15 | 1.72 | 1.86 | 1.61 | 1.82 |
PB Ratio | 1.44 | 1.52 | 1.88 | 1.74 | 1.70 | 1.84 |
P/TBV Ratio | 1.56 | 1.54 | 1.93 | 1.79 | 1.71 | 1.85 |
P/FCF Ratio | - | - | 10.82 | - | 21.06 | 82.94 |
P/OCF Ratio | 13.78 | 12.29 | 9.89 | - | 10.06 | 50.67 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 6, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.22 | 0.93 | 1.55 | 1.78 | 0.99 | 1.31 |
EV/EBITDA Ratio | 17.06 | 24.10 | 34.31 | 52.76 | 12.97 | 18.46 |
EV/EBIT Ratio | - | 2758.71 | - | - | 18.34 | 28.69 |
EV/FCF Ratio | - | - | 9.73 | - | 12.90 | 59.72 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 6, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 1.01 | 0.79 | 0.44 | 0.51 | 0.17 | 0.08 |
Debt / EBITDA Ratio | 9.89 | 8.11 | 4.66 | 6.77 | 1.42 | 0.72 |
Debt / FCF Ratio | - | - | 2.53 | - | 2.08 | 3.47 |
Net Debt / Equity Ratio | 0.29 | -0.14 | -0.33 | -0.14 | -0.55 | -0.64 |
Net Debt / EBITDA Ratio | 5.58 | -2.84 | -6.65 | -4.51 | -6.81 | -8.98 |
Net Debt / FCF Ratio | -0.78 | 6.80 | -1.88 | 1.52 | -6.77 | -29.06 |
Asset Turnover | 0.67 | 0.65 | 0.60 | 0.57 | 0.75 | 0.80 |
Inventory Turnover | 4.69 | 5.79 | 4.12 | 3.67 | 5.91 | 7.91 |
Quick Ratio | 1.51 | 1.92 | 2.02 | 1.93 | 2.53 | 2.72 |
Current Ratio | 1.91 | 2.21 | 2.37 | 2.39 | 2.89 | 2.99 |
Return on Equity (ROE) | -0.49% | 0.45% | 0.24% | -1.04% | 3.11% | 4.87% |
Return on Assets (ROA) | -0.26% | 0.01% | -0.10% | -0.54% | 2.51% | 2.28% |
Return on Invested Capital (ROIC) | -0.76% | 0.06% | -0.21% | -2.16% | 9.82% | 11.18% |
Return on Capital Employed (ROCE) | -0.50% | 0.00% | -0.20% | -1.00% | 5.20% | 4.60% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 6, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -0.41% | 0.31% | 0.20% | -0.51% | 1.85% | 2.40% |
FCF Yield | -25.55% | -1.40% | 9.24% | -5.39% | 4.75% | 1.21% |
Dividend Yield | - | - | - | - | 0.82% | 2.03% |
Payout Ratio | - | - | - | - | 118.16% | 187.38% |
Buyback Yield / Dilution | - | - | - | 0.10% | -0.93% | -10.99% |
Total Shareholder Return | - | - | - | 0.10% | -0.11% | -8.97% |